PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial Meeting Abstract
| Authors: | Prat, A.; Brase, J. C.; Cheng, Y.; Nuciforo, P.; Paré, L.; Pascual, T.; Martínez, D.; Galván, P.; Vidal, M.; Adamo, B.; Hortobagyi, G.; Baselga, J.; Ciruelos, E. |
| Abstract Title: | PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial |
| Meeting Title: | 11th European Breast Cancer Conference (EBCC-11) |
| Journal Title: | European Journal of Cancer |
| Volume: | 92 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2018 Mar 21-23 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-04-01 |
| Start Page: | S117 |
| Language: | English |
| ACCESSION: | WOS:000429103100316 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(18)30574-4 |
| Notes: | Meeting Abstract: 404 (PB-037) -- Source: Wos |
